TBPH Q1 2024 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+39.2% YoY

Gross Profit

$6M38.2% margin

Operating Income

-$11M-77.3% margin

Net Income

-$12M-80.4% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-17.4%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$371M

Total Liabilities

$166M

Stockholders' Equity

$205M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$10M	+39.2%
Gross Profit	$6M	-$4M	+233.2%
Operating Income	-$11M	-$25M	+55.0%
Net Income	-$12M	-$22M	+47.2%

Revenue Segments

YUPELRI Monotherapy

$19M57%

Collaboration revenue

$15M43%